NASDAQ:BPTH Bio-Path (BPTH) Stock Price, News & Analysis $1.77 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.73▼$1.8250-Day Range$1.64▼$3.2352-Week Range$1.59▼$23.00Volume13,175 shsAverage Volume1.12 million shsMarket Capitalization$3.68 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends Get Bio-Path alerts: Email Address Bio-Path MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,029.9% Upside$20.00 Price TargetShort InterestHealthy5.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.53) to ($3.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.58 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBio-Path has only been the subject of 1 research reports in the past 90 days.Read more about Bio-Path's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.35% of the float of Bio-Path has been sold short.Short Interest Ratio / Days to CoverBio-Path has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Path has recently decreased by 23.45%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBio-Path does not currently pay a dividend.Dividend GrowthBio-Path does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPTH. Previous Next 3.6 News and Social Media Coverage News SentimentBio-Path has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bio-Path this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for BPTH on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat Follows1 people have added Bio-Path to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bio-Path insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.05% of the stock of Bio-Path is held by insiders.Percentage Held by InstitutionsOnly 5.74% of the stock of Bio-Path is held by institutions.Read more about Bio-Path's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bio-Path are expected to grow in the coming year, from ($5.53) to ($3.65) per share.Price to Book Value per Share RatioBio-Path has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bio-Path's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agency5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About Bio-Path Stock (NASDAQ:BPTH)Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Read More BPTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPTH Stock News HeadlinesJuly 8, 2024 | globenewswire.comBio-Path Holdings Provides Clinical Update and Expansion PlansJune 14, 2024 | investorplace.comWhy Is Bio-Path (BPTH) Stock Up 20% Today?July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 14, 2024 | globenewswire.comBio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association CongressJune 5, 2024 | globenewswire.comBio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesJune 3, 2024 | globenewswire.comBio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual MeetingMay 24, 2024 | globenewswire.comBio-Path Holdings to Present Data at 2024 European Hematology Association CongressMay 23, 2024 | globenewswire.comBio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual MeetingJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 16, 2024 | finance.yahoo.comBio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...May 15, 2024 | finanznachrichten.deBio-Path Holdings, Inc.: Bio-Path Holdings Reports First Quarter 2024 Financial ResultsMay 15, 2024 | msn.comBio-Path GAAP EPS of -$4.88 misses by $0.34May 15, 2024 | globenewswire.comBio-Path Holdings Reports First Quarter 2024 Financial ResultsMay 8, 2024 | globenewswire.comBio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024May 2, 2024 | benzinga.comLooking Into Bio-Path Hldgs's Recent Short InterestApril 19, 2024 | globenewswire.comBio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 18, 2024 | msn.comCrude Oil Edges Lower; Bio-Path Holdings Shares Spike HigherApril 18, 2024 | msn.comWhy Bio-Path Stock Is SoaringSee More Headlines Receive BPTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BPTH CUSIPN/A CIK1133818 Webwww.biopathholdings.com Phone(832) 742-1357FaxN/AEmployees10Year Founded2007Price Target and Rating Average Stock Price Target$20.00 High Stock Price Target$20.00 Low Stock Price Target$20.00 Potential Upside/Downside+1,029.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,037.30% Return on Assets-337.80% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book2.49Miscellaneous Outstanding Shares2,080,000Free Float2,017,000Market Cap$3.68 million OptionableOptionable Beta0.28 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Peter H. Nielsen MBA (Age 75)Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer Comp: $696.24kMr. Douglas P. Morris (Age 68)Co-Founder, Director of Investor Relations, Secretary & Director Comp: $73.74kMr. Michael Hickey M.B.A.VP of Clinical OperationsMr. Anthony PriceSenior Vice President of Finance, Accounting & AdministrationDr. Ana Tari Ashizawa Ph.D.MBA, Senior Vice President of Research, Development & Clinical DesignKey CompetitorsTalpheraNASDAQ:TLPHChemomab TherapeuticsNASDAQ:CMMBKiora PharmaceuticalsNASDAQ:KPRXBriaCell TherapeuticsNASDAQ:BCTXUniverse PharmaceuticalsNYSE:UPCView All Competitors BPTH Stock Analysis - Frequently Asked Questions How have BPTH shares performed this year? Bio-Path's stock was trading at $9.26 at the start of the year. Since then, BPTH stock has decreased by 80.9% and is now trading at $1.77. View the best growth stocks for 2024 here. How were Bio-Path's earnings last quarter? Bio-Path Holdings, Inc. (NASDAQ:BPTH) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($4.88) EPS for the quarter, missing the consensus estimate of ($4.54) by $0.34. When did Bio-Path's stock split? Bio-Path's stock reverse split on the morning of Friday, February 23rd 2024. The 1-20 reverse split was announced on Friday, February 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Bio-Path? Shares of BPTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Bio-Path own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), Trevena (TRVN). This page (NASDAQ:BPTH) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPTH Stock Alerts